LUAA 399599

Drug Profile

LUAA 399599

Alternative Names: LU AA39959

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lundbeck A/S
  • Class Antipsychotics
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bipolar depression; Bipolar disorders; Schizophrenia

Most Recent Events

  • 17 Mar 2010 Discontinued - Phase-II for Bipolar disorders in Denmark (PO)
  • 17 Mar 2010 Discontinued - Phase-II for Schizophrenia in Denmark (PO)
  • 04 Mar 2010 Preclinical development is ongoing and Lundbeck will make a decision on future development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top